North Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health

ClinicalTrials.gov ID: NCT07746999

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07746999. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary Objective: Assess disparities in liver health outcomes among transgender individuals on GAHT by evaluating liver function markers (transaminases, bilirubin levels, etc), as well as liver elasticity and presence of liver steatosis or Nonalcoholic Fatty Liver Disease (NAFLD) through FibroScan. A total of 60 participants will be recruited throughout the study, with a ratio of 1:1 between transgender participants who have been on GAHT more than 6 months ( = or \> 182 days), and transgender participants who have been on GAHT for less than 6 months ( \< 181 days) at the start of the study. Secondary Objectives: Assess liver health-related risk factors (e.g. obesity, alcohol consumption) in transgender population. Investigate the association between specific hormone regimens and liver function in transgender individuals. Explore potential modifiers of liver health outcomes, such as age, social barriers determinants of health, duration of hormone therapy and adherence to medical guidelines. Change in Quality of Life from baseline to last study visit.

Study identification

NCT ID: NCT07746999
Recruitment status: Enrolling by invitation
Study type: Observational
Phase: Not listed
Lead sponsor: Corey DeStefano; Other
Enrollment: 60 participants

Conditions and interventions

Conditions

HEPATITIS C (HCV)

Interventions

Not listed

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 15, 2025 (Actual)
Primary completion: Mar 15, 2027 (Estimated)
Completion: Mar 15, 2027 (Estimated)
Last update posted: Aug 5, 2026

2025 – 2027

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)	Newark	New Jersey	07103	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07746999, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 5, 2026 · Synced Nov 15, 2026